MedTrace Logo

Adherence of Iron Succinylate Therapy in Pregnancy

NCT03873571 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2023-02-15

No results posted yet for this study

Summary

According to the World Health Organization (WHO), anemia is the most common disease, affecting \>1.5 billion people worldwide. Furthermore, iron deficiency anemia (IDA) accounts for 50% of cases of anemia. IDA is common during pregnancy and the postpartum period, and can lead to serious maternal and fetal complications. Measurement of serum ferritin has the highest sensitivity and specificity for diagnosis of IDA unless there is a concurrent inflammatory condition. The lower threshold value for hemoglobin (Hb) in pregnant women is \<11 g/dL during the 1st and 3rd trimesters, and \<10.5 g/dL during the 2nd trimester. In postpartum period a Hb concentration \<10 g/dL indicates clinically significant anemia. Oral iron therapy is given as the first-line treatment for IDA.

Conditions

Sponsors & Collaborators

  • Elpen Pharmaceutical Co. Inc.

    lead INDUSTRY

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-12-30
Primary Completion
2023-12-30
Completion
2023-12-30

Countries

  • Greece

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03873571 on ClinicalTrials.gov